Selected research
Industry Research
RNA-Targeted Small Molecule Drugs Industry Research Report 2026
Market perspective
The global RNA-Targeted Small Molecule Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the RNA-Targeted Small Molecule Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the RNA-Targeted Small Molecule Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the RNA-Targeted Small Molecule Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of RNA-Targeted Small Molecule Drugs include Roche, Novartis, PTC Therapeutics, Biogen, Accent Therapeutics, Anima Biotech, Arrakis Pharmaceuticals, Epics Therapeutics and Expansion Therapeutics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global RNA-Targeted Small Molecule Drugs market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to RNA-Targeted Small Molecule Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
RNA-Targeted Small Molecule Drugs Market by Company
Roche
Novartis
PTC Therapeutics
Biogen
Accent Therapeutics
Anima Biotech
Arrakis Pharmaceuticals
Epics Therapeutics
Expansion Therapeutics
Gotham Therapeutics
H3 Biomedicine
Ribometrix
Skyhawk Therapeutics
STORM Therapeutics
Twentyeight-Seven Therapeutics
RNA-Targeted Small Molecule Drugs Segment by Type
mRNA Translation Regulation
RNA Splicing Modification
Direct RNA Targeting
Indirect RNA Targeting - Epitranscriptomics
RNA-Targeted Small Molecule Drugs Segment by Application
SMA
Oncology
Lung Fibrosis
Huntington's Disease
Others
RNA-Targeted Small Molecule Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA-Targeted Small Molecule Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of RNA-Targeted Small Molecule Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA-Targeted Small Molecule Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of RNA-Targeted Small Molecule Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- mRNA Translation Regulation
- RNA Splicing Modification
- Direct RNA Targeting
- Indirect RNA Targeting - Epitranscriptomics
Applications
- SMA
- Oncology
- Lung Fibrosis
- Huntington's Disease
- Others
Companies covered
- Roche
- Novartis
- PTC Therapeutics
- Biogen
- Accent Therapeutics
- Anima Biotech
- Arrakis Pharmaceuticals
- Epics Therapeutics
- Expansion Therapeutics
- Gotham Therapeutics
- H3 Biomedicine
- Ribometrix
- Skyhawk Therapeutics
- STORM Therapeutics
- Twentyeight-Seven Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 RNA-Targeted Small Molecule Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 mRNA Translation Regulation
- 2.2.3 RNA Splicing Modification
- 2.2.4 Direct RNA Targeting
- 2.2.5 Indirect RNA Targeting - Epitranscriptomics
- 2.3 RNA-Targeted Small Molecule Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 SMA
- 2.3.3 Oncology
- 2.3.4 Lung Fibrosis
- 2.3.5 Huntington's Disease
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 RNA-Targeted Small Molecule Drugs Breakdown Data by Type
- 3.1 Global RNA-Targeted Small Molecule Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global RNA-Targeted Small Molecule Drugs Forecasted Market Size by Type (2027-2032)
4 RNA-Targeted Small Molecule Drugs Breakdown Data by Application
- 4.1 Global RNA-Targeted Small Molecule Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global RNA-Targeted Small Molecule Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global RNA-Targeted Small Molecule Drugs Market Perspective (2021-2032)
- 5.2 Global RNA-Targeted Small Molecule Drugs Growth Trends by Region
- 5.2.1 Global RNA-Targeted Small Molecule Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 RNA-Targeted Small Molecule Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 RNA-Targeted Small Molecule Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 RNA-Targeted Small Molecule Drugs Market Dynamics
- 5.3.1 RNA-Targeted Small Molecule Drugs Industry Trends
- 5.3.2 RNA-Targeted Small Molecule Drugs Market Drivers
- 5.3.3 RNA-Targeted Small Molecule Drugs Market Challenges
- 5.3.4 RNA-Targeted Small Molecule Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top RNA-Targeted Small Molecule Drugs Players by Revenue
- 6.1.1 Global Top RNA-Targeted Small Molecule Drugs Players by Revenue (2021-2026)
- 6.1.2 Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global RNA-Targeted Small Molecule Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of RNA-Targeted Small Molecule Drugs Head Office and Area Served
- 6.4 Global RNA-Targeted Small Molecule Drugs Players, Product Type & Application
- 6.5 Global RNA-Targeted Small Molecule Drugs Manufacturers Established Date
- 6.6 Global RNA-Targeted Small Molecule Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America RNA-Targeted Small Molecule Drugs Market Size (2021-2032)
- 7.2 North America RNA-Targeted Small Molecule Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026)
- 7.4 North America RNA-Targeted Small Molecule Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe RNA-Targeted Small Molecule Drugs Market Size (2021-2032)
- 8.2 Europe RNA-Targeted Small Molecule Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026)
- 8.4 Europe RNA-Targeted Small Molecule Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America RNA-Targeted Small Molecule Drugs Market Size (2021-2032)
- 10.2 South America RNA-Targeted Small Molecule Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026)
- 10.4 South America RNA-Targeted Small Molecule Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Roche
- 12.1.1 Roche Company Information
- 12.1.2 Roche Business Overview
- 12.1.3 Roche Revenue in RNA-Targeted Small Molecule Drugs Business (2021-2026)
- 12.1.4 Roche RNA-Targeted Small Molecule Drugs Product Portfolio
- 12.1.5 Roche Recent Developments
- 12.2 Novartis
- 12.2.1 Novartis Company Information
- 12.2.2 Novartis Business Overview
- 12.2.3 Novartis Revenue in RNA-Targeted Small Molecule Drugs Business (2021-2026)
- 12.2.4 Novartis RNA-Targeted Small Molecule Drugs Product Portfolio
- 12.2.5 Novartis Recent Developments
- 12.3 PTC Therapeutics
- 12.3.1 PTC Therapeutics Company Information
- 12.3.2 PTC Therapeutics Business Overview
- 12.3.3 PTC Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2021-2026)
- 12.3.4 PTC Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
- 12.3.5 PTC Therapeutics Recent Developments
- 12.4 Biogen
- 12.4.1 Biogen Company Information
- 12.4.2 Biogen Business Overview
- 12.4.3 Biogen Revenue in RNA-Targeted Small Molecule Drugs Business (2021-2026)
- 12.4.4 Biogen RNA-Targeted Small Molecule Drugs Product Portfolio
- 12.4.5 Biogen Recent Developments
- 12.5 Accent Therapeutics
- 12.5.1 Accent Therapeutics Company Information
- 12.5.2 Accent Therapeutics Business Overview
- 12.5.3 Accent Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2021-2026)
- 12.5.4 Accent Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
- 12.5.5 Accent Therapeutics Recent Developments
- 12.6 Anima Biotech
- 12.6.1 Anima Biotech Company Information
- 12.6.2 Anima Biotech Business Overview
- 12.6.3 Anima Biotech Revenue in RNA-Targeted Small Molecule Drugs Business (2021-2026)
- 12.6.4 Anima Biotech RNA-Targeted Small Molecule Drugs Product Portfolio
- 12.6.5 Anima Biotech Recent Developments
- 12.7 Arrakis Pharmaceuticals
- 12.7.1 Arrakis Pharmaceuticals Company Information
- 12.7.2 Arrakis Pharmaceuticals Business Overview
- 12.7.3 Arrakis Pharmaceuticals Revenue in RNA-Targeted Small Molecule Drugs Business (2021-2026)
- 12.7.4 Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Product Portfolio
- 12.7.5 Arrakis Pharmaceuticals Recent Developments
- 12.8 Epics Therapeutics
- 12.8.1 Epics Therapeutics Company Information
- 12.8.2 Epics Therapeutics Business Overview
- 12.8.3 Epics Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2021-2026)
- 12.8.4 Epics Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
- 12.8.5 Epics Therapeutics Recent Developments
- 12.9 Expansion Therapeutics
- 12.9.1 Expansion Therapeutics Company Information
- 12.9.2 Expansion Therapeutics Business Overview
- 12.9.3 Expansion Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2021-2026)
- 12.9.4 Expansion Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
- 12.9.5 Expansion Therapeutics Recent Developments
- 12.10 Gotham Therapeutics
- 12.10.1 Gotham Therapeutics Company Information
- 12.10.2 Gotham Therapeutics Business Overview
- 12.10.3 Gotham Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2021-2026)
- 12.10.4 Gotham Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
- 12.10.5 Gotham Therapeutics Recent Developments
- 12.11 H3 Biomedicine
- 12.11.1 H3 Biomedicine Company Information
- 12.11.2 H3 Biomedicine Business Overview
- 12.11.3 H3 Biomedicine Revenue in RNA-Targeted Small Molecule Drugs Business (2021-2026)
- 12.11.4 H3 Biomedicine RNA-Targeted Small Molecule Drugs Product Portfolio
- 12.11.5 H3 Biomedicine Recent Developments
- 12.12 Ribometrix
- 12.12.1 Ribometrix Company Information
- 12.12.2 Ribometrix Business Overview
- 12.12.3 Ribometrix Revenue in RNA-Targeted Small Molecule Drugs Business (2021-2026)
- 12.12.4 Ribometrix RNA-Targeted Small Molecule Drugs Product Portfolio
- 12.12.5 Ribometrix Recent Developments
- 12.13 Skyhawk Therapeutics
- 12.13.1 Skyhawk Therapeutics Company Information
- 12.13.2 Skyhawk Therapeutics Business Overview
- 12.13.3 Skyhawk Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2021-2026)
- 12.13.4 Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
- 12.13.5 Skyhawk Therapeutics Recent Developments
- 12.14 STORM Therapeutics
- 12.14.1 STORM Therapeutics Company Information
- 12.14.2 STORM Therapeutics Business Overview
- 12.14.3 STORM Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2021-2026)
- 12.14.4 STORM Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
- 12.14.5 STORM Therapeutics Recent Developments
- 12.15 Twentyeight-Seven Therapeutics
- 12.15.1 Twentyeight-Seven Therapeutics Company Information
- 12.15.2 Twentyeight-Seven Therapeutics Business Overview
- 12.15.3 Twentyeight-Seven Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2021-2026)
- 12.15.4 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
- 12.15.5 Twentyeight-Seven Therapeutics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst